Neucardin is under clinical development by Zensun (Shanghai) Sci & Tech and currently in Phase II for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase II drugs for Congestive Heart Failure (Heart Failure) have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Neucardin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Neucardin overview

Neucardin (recombinant human neuregulin-1, rhNRG-1) is under development for the treatment of chronic heart failure, myocardial infarction, systolic heart failure and diastolic heart failure (heart failure with preserved ejection fraction). The drug candidate is administered through intravenous route as a bolus or a drip and subcutaneous route. The drug candidate is a genetically engineered recombinant peptide fragment of neuregulin-1 (beta2a isoform). It acts by targeting receptor tyrosine protein kinase 4. It was also under development for the treatment of stroke.

Zensun (Shanghai) Sci & Tech overview

Zensun (Shanghai) Sci & Tech (Zensun Shanghai) is a biopharmaceutical company that conducts research and development of bio-therapeutic drugs for the heart failure, breast cancer and other life-threatening diseases. The company discovers new medicines using novel disease specific targets and inventive technologies. Its products include Neucardin, a treatment for heart failure; rhErbB3-f, a therapeutic tumor vaccine for cancer treatment; and ZS-05, a treatment for urinary tract infection. The company serves in the areas Alzheimer’s disease. Zensun Shanghai is headquartered in Shanghai, China.

For a complete picture of Neucardin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.